Opinion

Video

Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

Panelists discuss how treatment continuation decisions for amyloid-targeting therapies involve comprehensive assessment of multiple factors including cognitive and functional changes measured through standardized tools, occurrence and severity of adverse events, treatment adherence capabilities, impact on patient/caregiver quality of life, disease progression rate, emerging safety signals, and ongoing dialogue about evolving treatment goals and expectations.

Video content above is prompted by the following:

  • How do you decide whether to continue or discontinue treatment with an amyloid-targeting therapy?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
1 expert is featured in this series.
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo